# A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

> **NCT05025631** · PHASE2 · COMPLETED · sponsor: **Zhen-Yu Ding** · enrollment: 29 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT05025631
- **Lead sponsor:** Zhen-Yu Ding
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-06
- **Primary completion:** 2022-10-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025631, "A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05025631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*